An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis

PDL BioPharma, Inc.300 enrolled

Overview

To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Ulcerative Colitis

Interventions

Visilizumab (Nuvion®; HuM291)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Previous participation in a visilizumab study of IVSR-UC. * Disease progression while enrolled in a previous visilizumab study, and subsequent treatment with salvage therapy. Exclusion Criteria: * Unable to understand the purpose and risks of the study, or unwilling or unable to provide a signed and dated informed consent. * For U.S. sites, unwilling or unable to provide authorization to use protected health information.

Locations (40)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.